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To the Editor: We read with great interest the article by
Mrug et al.1 regarding the importance of innate-immunity
genes in the physiopathology of autosomal recessive poly-
cystic kidney disease. We previously published the analysis of
Hannover-Sprague-Dawley (Han:SPRD) rat’s transcriptome,
with emphasis on the function of genes involved in formation
and metabolism of extracellular matrix.2 Supporting
Mrug’s article, we present unpublished results of our
microarrays regarding the innate-immunity genes in the
kidney of Han:SPRD rats. We used Agilent (Santa Clara, CA,
USA) microarrays to study the transcriptome.2 The results
are presented in Table 1. We confirmed the overexpression
of nine complement-component genes in the polycystic
kidney of Han:SPRD rat. We also confirmed the over-
expression of acute-phase reactant genes like Hp, Tf, and
Cp. We agree with the authors who wrote that in this
model, activated macrophage is present, and we bring new
markers of its presence (overexpression of Runx1, Il24,
Mgl, scya20, for example). The majority of cysts in Han:SPRD
rat, unlike cpk mouse, are derived from the proximal tubule.
It would be interesting to explore whether cysts derived
from the proximal tubule, like those derived from the
collecting ducts, are able to produce C3.1 This collection of
data could explain the effect of endotoxin-free environment
on the development of polycystic kidney disease,3 the
efficacy of methylprednisolone in the Han:SPRD rat
model in slowing down the progression of polycystic
kidney disease,4 and suggest a common role of innate
immune response in different forms of polycystic kidney
disease.
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Table 1 | Overexpressed innate-immunity genes in Han:SPRD
rat
Gene
Expression
in Mrug’s
article1
Fold
change Protein
Complement-component genes
Cfd Increased 2.14 Adipsin (complement
factor D)
C1qb Increased 1.84 Complement component 1,
q-subcomponent,
b-polypeptide
C1s — 1.57 Complement component 1,
s-subcomponent
Serping1 Increased 1.73 C1 inhibitor
C3 Increased 2.55 Complement component 3
C4a — 2.85 Complement component 4a
C7 — 1.51 Complement component 7
precursor
Cfh — 1.37 Complement component
factor H
Clu Increased 2.12 Clusterin
Coagulation factor genes
F2 — 2.03 Coagulation factor II
F3 — 1.69 Coagulation factor III
Serpine1 Increased 2.14 Serine (or cysteine) proteinase
inhibitor, clade E, member 1
Fgg — 2.51 Fibrinogen
Acute-phase reactant genes
Hp Increased 3.3 Haptoglobin
Tf — 1.98 Transferrin
Cp — 2.25 Ceruloplasmin
Arg1 Increased 1.8 Arginase 1
Hmox1 — 1.95 Heme oxygenase 1
Lcn2 Increased 2.23 Lipocalin 2
Macrophage-associated markers
Runx1 — 1.58 Runt-related transcription
factor 1
Table 1 | Continued
Gene
Expression
in Mrug’s
article1
Fold
change Protein
Mgl1 — 1.73 Macrophage galactose
N-acetyl-galactosamine-
specific lectin
Elf1 — 1.46 E74-like factor 1
Il24 — 1.96 Interleukin 24
Timp2 Increased 1.74 Tissue inhibitor of
metallopeptidase 2
Ifngr1 Increased 1.86 Interferon-g receptor 1
Abca1 Increased 1.76 ATP-binding cassette, sub-
family A (ABC1), member 1
Cpe — 2.2 Carboxypeptidase E
Scya20 — 1.41 Small inducible cytokine
subfamily A20
Lpl — 1.71 Lipoprotein lipase
Trif-pending — 1.31 Trif
TORID — 1.73 Torid
Mal — 2.09 Mal protein
Gilz — 2.61 Glucocorticoid-induced
leucine zipper
Ctsd — 2.06 Cathepsin D
Ctsk — 2.04 Cathepsin D
Lyz — 2.04 Lysozyme
Fn1 Increased 1.53 Fibronectin
Vim — 1.99 Vimentin
Adamts1 — 1.53 A disintegrin-like and
metallopeptidase (reprolysin
type) with thrombospondin
type 1 motif, 1
Lgals3 — 1.68 Lectin, galactose binding,
soluble 3
Mmp14 — 1.43 Matrix metallopeptidase 14
Mmp7 — 2.12 Matrix metallopeptidase 7
— indicates no change in Mrug’s article.
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Response to ‘Overexpression of
complement-component genes
in Han:SPRD rats a model of
polycystic kidney disease’
Kidney International (2008) 73, 1325; doi:10.1038/ki.2008.52
We appreciate the letter submitted by Dr Burtey and
co-workers in response to our recent report ‘Overexpression
of innate immune response genes in a model of recessive
polycystic kidney disease’.1 As noted in their letter,2 these
investigators observed that, similar to our observations in
the cpk mouse model, genes encoding multiple innate
immune factors, including complement system compo-
nents, were overexpressed in Han:SPRD-Cy rat kidneys.
Furthermore, in reviewing the table in their letter, we note
additional gene expression similarities between these two
models. For example, in cpk kidneys, we also observed
increased expression of Adamts1, Ctsd, Ctsk, Hmox1, Lyz
(under alias Lzp-s), Mmp14, and Vim. In addition, among
the genes overexpressed in Han:SPRD-Cy kidneys, we have
also observed increased expression of F3, Lgals3, Mal, and
Runx1 in cpk kidneys (data not shown in our original
report). These significant parallels in gene expression
profiles indicate that similar immune response pathways
are activated in kidneys from two phenotypically distinct
rodent models, suggesting that this perturbation may be a
common signature of polycystic kidney disease.
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Need for a more realistic cut-off
GFR value to define chronic renal
failure
Kidney International (2008) 73, 1325–1326; doi:10.1038/ki.2008.54
To the Editor: We read with interest the article titled
‘Age- and gender-specific reference values of estimated GFR
in Caucasians: the Nijmegen Biomedical Study.’ by Wetzels
et al.,1 and the commentary by Poggio et al.2 titled ‘Can we
do better than a single estimated GFR threshold when
screening for chronic kidney disease?’ published in the
September 2007 issue. We have performed a similar work in
Indian population where we have measured glomerular
filtration rate (GFR) in 610 healthy adults and demonstrated
a mean GFR of 81.4 ml min1 compared with 83–85 ml min1
reported by Wetzels et al.1,3
The definition of decreased GFR relies on an under-
standing of the ‘normal’ GFR range. The Kidney Disease
Outcome Quality Initiative guideline accepts normal GFR as
120 ml min1 and a 50% reduction in GFR (o60 ml min1)
constitutes chronic renal failure (CRF).4 It is universally
accepted that GFR declines relentlessly with age; however,
Kidney Disease Outcome Quality Initiative guideline assumes
that GFR is stable between 18 and 70 years. This assumption
allows a single cut-off GFR value for CRF. However, as has
been demonstrated by Wetzels et al., a 60 ml min1 cut-off
tends to over-diagnose CRF. This problem gets accentuated in
India, where normal GFR is itself lower by 2530%. GFR of
a 20-year-old Indian ranges from 89 to 109 ml min1 and
a 50% reduction from normal translates into 45 ml min1.
We agree with Wetzels et al. that GFR of 60 ml min1 cannot
be used to define CRF. Consideration should be given to
reduce the cut-off value for defining CRF, and we believe
45 ml min1 is more realistic in the Indian population.
1. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M.
Age- and gender-specific reference values of estimated GFR in
Caucasians: the Nijmegen Biomedical Study. Kidney Int 2007; 72: 632–637.
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